# Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

> **NCT03855917** · PHASE4 · UNKNOWN · sponsor: **Kirby Institute** · enrollment: 30 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir 400mg [Sovaldi]
- **DRUG:** Glecaprevir/pibrentasvir (300mg/120mg)

## Key facts

- **NCT ID:** NCT03855917
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-11
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03855917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03855917, "Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03855917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*